March 27, 2020 -- Atum has granted commercial and academic laboratories free access to its Leap-In Transposase protein production platform for use in creating tools and resources to battle the COVID-19 pandemic.
The platform contains a variety of viral proteins, antibodies, interleukins, and related protein molecules that are being evaluated in COVID-19 clinical trials. It can also help with the rapid production of commercial-grade protein.
Laboratories can use the platform to develop diagnostic tools, vaccines, and protein-based therapies to help combat the COVID-19 pandemic. Atum is fully operational and currently processing rush orders, the company noted.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
